Daja Herald’s Post

Celebrating CARBOGEN AMCIS colleague Luca Mannocci! It's great to see our scientists' talents highlighted in industry trade publications! Learn more about our ADC and bioconjugation expertise by starting the conversation today! How can we help bring your science to life? #ADCs #bioconjugation #CDMO #bringingyoursciencetolife

How has Propanc Biopharma optimized the formulation of their lead asset? We invite you to listen as Dr. Ralf Brandt, Propanc’s Scientific Advisory Board Member & Co-Inventor describes the process for taking the formulation from that compassionate use study that observed such positive results, and how the team further improved that same formulation with the goal of seeing even more efficacious results!   #propanc #ppcb #biopharma #cancer #oncology

Today we announced updated Phase 1b clinical data on ACTengine® IMA203 in metastatic melanoma patients and provided an update on the upcoming Phase 3 trial, “SUPRAME.” To read the full announcement, click here: https://lnkd.in/eF56m5ni We will also host a conference call and webcast today, October 10th at 9:00 am EDT / 3:00 pm CEST. The link to the webcast is available in the comments section below and in the press release. #pressrelease #companynews #melanoma #biotech #clinicaltrial #oncology #cancer #celltherapy #clinicaldata #biotechnews

Learn how to approach biomarker testing in lung and prostate cancer with real clinical example cases. In this on-demand webinar, three renowned experts, Prof. Fernando López-Ríos, Assoc. Prof. Alicia Morgans and Assoc. Prof. Herbert Loong, guide you through the difficulties and considerations of biomarker testing. PLUS, you can take the optional e-Learning to gain CME credits. Find it here: https://ow.ly/MSkJ50TzQ7M This educational programme is supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics. #MedEd #IndependentMedEd #Oncology #LungCancer #ProstateCancer #PrecisionMedicine

Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.

Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.

Watch our latest webinar! #CART #celltherapy #NK #webinar

ESMO 2024 Quick Takes with LARVOL: Guru Sonpavde, MD In this post-ESMO 2024 Quick Take, Dr. Guru Sonpavde, MD, shares his insights on the practice-changing NIAGARA trial. This randomized phase 3 study, involving approximately 1,000 patients, evaluated neoadjuvant gemcitabine, cisplatin, with or without durvalumab for muscle-invasive bladder cancer. The results showed significant improvements in both event-free survival (hazard ratio: 0.68) and overall survival (hazard ratio: 0.75), signaling a major shift in treatment approaches. Stay tuned for more post-ESMO reflections and updates on how this trial may shape future clinical practice. #ESMO24 #CancerResearch #NIAGARATrial #LARVOLQuickTake

Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.

Watch our webinar to learn how a large cancer center implemented PGDx elioTM tissue complete. Our panel discusses the benefits of rapid biomarker identification, the potential to provide a clearer path to reimbursement and the research opportunities that are possible with PGDx elio tissue complete.